Yantai Dongcheng Pharmaceutical Group (002675.SZ) Earnings Analysis

Yantai Dongcheng Pharmaceutical Group (002675.SZ) next reports earnings on 2026-08-22, consensus EPS 0.08 CNY. Last quarter (2026-03-26) it missed with EPS 0.06 CNY vs 0.16 CNY est (-62.5%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E 50.73.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 002675.SZ next report earnings?

Next earnings date2026-08-22
Consensus EPS estimate0.08 CNY
Revenue estimate0.62B

002675.SZ earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-260.06 CNY0.16 CNY-62.5%Miss
2025-10-290.07332 CNY0.07 CNY+4.7%Beat
2025-02-260.02056 CNY0.08 CNY-74.3%Miss
2024-10-280.06679 CNYn/an/an/a
2024-08-300.05756 CNYn/an/an/a

Beat rate: 1/3 (33%) over reported quarters with consensus data.

002675.SZ valuation and analyst view

Trailing P/E50.73
Trailing EPS0.2478 CNY
Price / book2.42
Dividend yield0.64%
Market cap10.42B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Yantai Dongcheng Pharmaceutical Group (002675.SZ)'s next earnings date?

Yantai Dongcheng Pharmaceutical Group is next scheduled to report on 2026-08-22, with a consensus EPS estimate of 0.08 CNY and revenue estimate of 0.62B.

Did 002675.SZ beat earnings last quarter?

In its 2026-03-26 report, 002675.SZ posted EPS of 0.06 CNY versus a 0.16 CNY estimate — a miss of 62.5%.

What is 002675.SZ's earnings track record?

Over the last 3 reported quarters with consensus data, 002675.SZ beat estimates 1 times (33%).

What is 002675.SZ's current P/E ratio and EPS?

002675.SZ trades at a trailing P/E of 50.73 on trailing EPS of 0.24779753491439785 CNY.

What do analysts rate 002675.SZ?

002675.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.